Emergent Biosolutions is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.
Emergent Biosolutions is a publicly traded company on NYQ using the ticker symbol EBS.
Detailed information on company financials and operating reports can be found here:
NYQ: EBS
Emergent Biosolutions Annual Revenue and Growth Rate
Note: Emergent Biosolutions's revenues are gauged from an analysis of company filings.
Investor Activity
Emergent Biosolutions has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
October 30, 2018
8
100%
$48 MM
Complete list of funding rounds and total amounts in the Company Report
Trademark Applications
Trademark applications show the products and services that Emergent Biosolutions is developing and marketing.
Emergent Biosolutions's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
EMERGENT BIO SERVICES Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing for others and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals
07/25/2023
MAKERS OF A BETTER WORLD Contract manufacturing in the field of pharmaceuticals; fill and finishing services, namely, clinical manufacturing of drug formulations for others to support clinical trials, commercial manufacturing for others and lyophilization, namely, freeze-drying services for others, in the field of pharmaceuticals
07/25/2023
PERFECTING YOUR FORMULA Downloadable digital marketing material, namely, downloadable electronic publications in the nature of brochures, booklets, informational cards, and newsletters in the fields of research and development in the pharmaceutical, biotechnology, and biodefense fields, contract development manufacturing operations, worldwide diseases, medical conditions, vaccinations and treatments
07/20/2020
See all trademarks and details in the Full Report.
Market Share of Emergent Biosolutions's Largest Competitors
A competitive analysis shows these companies are in the same general field as Emergent Biosolutions, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Emergent Biosolutions.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Emergent Biosolutions and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.